Liver Transplantation With Tregs at UCSF

Exclusion Criteria

• •Recipient:
• •Individuals who meet any of the following criteria will not be eligible for this study:
• •1. History of previous organ, tissue or cell transplant
• •2. For cytomegalovirus (CMV) antibody negative recipients, a (CMV) antibody positive donor
• •3. Known contraindication to cyclophosphamide or mesna
• •4. Serologic evidence of human immunodeficiency virus (HIV)-1/2 infection
• •5. The need for chronic anti-coagulation or anti-platelet agents other than aspirin that cannot be safely discontinued for a minimum of 1 week to safely perform a liver biopsy
• •6. End stage liver disease secondary to autoimmune etiology (autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis) or other contraindications to drug withdrawal
• •7. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule
• •8. Any condition that, in the opinion of the investigator, may interfere with study compliance
• •9. History of cardiac disease (ischemic heart disease requiring revascularization, history of or current treatment for dysrhythmia, or evidence of congestive heart failure), unless cleared by a cardiologist
• •10. Any past or current medical problems, treatments or findings that are not listed above, which, in the opinion of the investigator, may:
• •* pose additional risks from participation in the study,
• •* interfere with the candidate's ability to comply with study requirements, or
• •* impact the quality or interpretation of the data obtained from the study.
• •* This includes past, present or future enrollment in studies that affect eligibility at the time of everolimus (EVR) conversion
• •11. History of malignancy or any concomitant malignancy, except:
• •* hepatocellular carcinoma,
• •* completely treated in-situ cervical carcinoma, or
• •* completely treated basal cell carcinoma.
• •12. Chronic use of systemic glucocorticoids or other immunosuppressives, or biologic immunomodulators.
• •Living Donor:
• •Deceased Donor: